Iterum Therapeutics (ITRM) to Release Quarterly Earnings on Friday

Iterum Therapeutics (NASDAQ:ITRM) is projected to post its results before the market opens on Friday, February 6th. Analysts expect Iterum Therapeutics to post earnings of ($0.20) per share and revenue of $0.5050 million for the quarter.

Iterum Therapeutics (NASDAQ:ITRM) last released its quarterly earnings results on Friday, November 14th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.07). The firm had revenue of $0.39 million for the quarter.

Iterum Therapeutics Stock Down 2.7%

NASDAQ ITRM opened at $0.31 on Friday. The company has a 50 day moving average price of $0.37 and a 200 day moving average price of $0.59. The firm has a market cap of $16.69 million, a PE ratio of -0.42 and a beta of 2.87. Iterum Therapeutics has a 52 week low of $0.26 and a 52 week high of $1.75.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Iterum Therapeutics stock. Virtu Financial LLC bought a new stake in Iterum Therapeutics PLC (NASDAQ:ITRM) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 47,131 shares of the company’s stock, valued at approximately $32,000. Virtu Financial LLC owned approximately 0.10% of Iterum Therapeutics at the end of the most recent reporting period. 9.21% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Iterum Therapeutics in a research note on Monday, December 22nd. Wall Street Zen lowered shares of Iterum Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $9.00.

Iterum Therapeutics Company Profile

Iterum Therapeutics plc is a clinical-stage biopharmaceutical company focused on the development and commercialization of anti-infective products targeting drug-resistant bacterial infections. The company’s research efforts are centered on novel therapeutic agents designed to address serious community-acquired and hospital-acquired infections where current treatment options are limited by emerging resistance.

The company’s lead product candidate, sulopenem, is being evaluated in both intravenous and oral formulations for the treatment of complicated urinary tract infections (cUTI) and intra-abdominal infections (IAI).